← back to search

Evan Rosenbaum

Memorial Sloan Kettering Cancer Center · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Lung Cancer Treatments and Mutations.
h-index
17
citations
1,178
works
171
NIH funding
primary concept
email

Recent publications

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
Clinical Cancer Research 2024cited by 15position: middledoi
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group
ESMO Open 2024cited by 8position: middledoi
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms
The American Journal of Surgical Pathology 2024cited by 4position: middledoi
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Clinical Cancer Research 2023cited by 67position: middledoi
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
ESMO Open 2023cited by 24position: middledoi
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Nature Communications 2022cited by 199position: middledoi
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
Journal for ImmunoTherapy of Cancer 2022cited by 56position: firstdoi
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
Nature Communications 2022cited by 56position: middledoi
The impact of <i>MYC</i> gene amplification on the clinicopathological features and prognosis of radiation‐associated angiosarcomas of the breast
Histopathology 2021cited by 25position: middledoi
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing
Clinical Cancer Research 2020cited by 116position: middledoi
Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets
Modern Pathology 2019cited by 152position: firstdoi
Multicentre retrospective study of intravascular large B‐cell lymphoma treated at academic institutions within the United States
British Journal of Haematology 2019cited by 34position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

William D. Tap · Media Working Group5 papers (2019–2024)Sandra P. D’ Angelo · Memorial Sloan Kettering Cancer Center4 papers (2021–2024)Cristina R. Antonescu · Cornell University4 papers (2019–2023)Sujana Movva · Memorial Sloan Kettering Cancer Center3 papers (2022–2024)Mary Louise Keohan · Memorial Sloan Kettering Cancer Center3 papers (2022–2024)Samuel Singer · North Shore University Hospital3 papers (2019–2023)Ciara M. Kelly · Memorial Sloan Kettering Cancer Center3 papers (2022–2024)Viswatej Avutu · St. Jude Children's Research Hospital3 papers (2022–2024)Ping Chi · Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University3 papers (2022–2024)Mrinal M. Gounder · Weill Cornell Medicine3 papers (2022–2024)Jason E. Chan · Cornell University3 papers (2022–2024)Mark A. Dickson · South Tyneside and Sunderland NHS Foundation Trust3 papers (2022–2024)Allison L. Richards · Memorial Sloan Kettering Cancer Center2 papers (2022–2023)Li‐Xuan Qin · Memorial Sloan Kettering Cancer Center2 papers (2023–2024)Bin Xu · Memorial Sloan Kettering Cancer Center2 papers (2019–2021)Martee L. Hensley · Memorial Sloan Kettering Cancer Center2 papers (2020–2024)Mark T.A. Donoghue · Columbus Oncology and Hematology Associates2 papers (2020–2022)Joseph P. Erinjeri · Cornell University2 papers (2023–2024)Benjamin A. Nacev · University of Pittsburgh2 papers (2022–2023)Jason Kaplan · National Cancer Center1 papers (2019–2019)